The strong beat and second consecutive guidance raise confirm robust demand across physician, hospital, and consumer channels. Traders should expect a positive reaction, but monitor the 2.8% decline in revenue per requisition and slight margin compression as potential headwinds. The raised cash flow guidance to ~$1.80B supports continued capital returns.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 23 $227.90entry
- T+1 · 4mo ago −0.02%α −0.12% · $227.86
- T+5 · 4mo ago +2.81%α +2.33% · $234.30
- T+20 · 3mo ago +5.88%α +2.57% · $241.30
- T+60 · 4w ago +4.94%α +0.38% · $239.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Quest Diagnostics reported Q2 2026 adjusted EPS of $3.12, beating consensus of $2.82 by 10.6%, and revenue of $3.04B, beating $2.97B by 2.5%. The company raised full-year 2026 guidance for the second consecutive quarter, now expecting revenue of $11.95B-$12.05B and adjusted EPS of $11.05-$11.25, driven by 10.2% revenue growth and 19.1% adjusted EPS growth.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $3.04B, up 10.2% YoY (10.0% organic)
- Adjusted diluted EPS $3.12, up 19.1% YoY, beat consensus by 10.6%
- Full-year 2026 revenue guidance raised to $11.95B-$12.05B (prior $11.78B-$11.90B)
- Full-year 2026 adjusted EPS guidance raised to $11.05-$11.25 (prior $10.63-$10.83)
- Operating cash flow $597M in Q2, up 9.7% YoY; capex $138M
- Requisition volume grew 13.1% (organic 13.0%), but revenue per requisition declined 2.8%
Financial Impact
Revenue beat by ~$73M; EPS beat by $0.30; guidance raised by ~$170M at midpoint for revenue and $0.42 for adjusted EPS
Risk Factors
- Revenue per requisition declined 2.8% YoY, indicating mix shift or pricing pressure
- Reported operating margin contracted to 15.1% from 15.9% (adjusted 16.5% vs 16.9%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001022079-26-000067 |
| Document: dgx-20260723.htm | 0001022079-26-000067 |
| Document: 0001022079-26-000067-index-headers.html | 0001022079-26-000067 |
| Document: 0001022079-26-000067-index.html | 0001022079-26-000067 |
| Document: 0001022079-26-000067.txt | 0001022079-26-000067 |
| 8-K Data (Synthetic) | 0001022079-26-000067 |
Track record
23 reports on DGX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20263d ago Insider Cluster Neutral 2/10 Entry $259.65 Now $261.92 +0.87% settles Feb 11
- Nov 10, 20265d ago Press Release Neutral 2/10 Entry $258.69 Now $261.92 +1.25% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $258.44 Now $261.92 +1.35% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $259.67 Now $261.92 +0.87% settles Feb 5
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $259.67 Now $261.92 +0.87% settles Feb 5
- Nov 5, 202610d ago 3 Neutral 2/10 Entry $255.63 Now $261.92 +2.46% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $247.06 Now $261.92 +6.01% settles Feb 1
- Nov 3, 202613d ago 144 Neutral 3/10 Entry $247.06 Now $261.92 +6.01% settles Feb 1
- Oct 27, 202619d ago Institutional Cluster Mixed 3/10 Entry $245.62 Now $261.92 +6.64% settles Jan 26
- Oct 26, 202621d ago 144 Neutral 2/10 Entry $242.95 Now $261.92 +7.81% settles Jan 22
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers